Pharmacokinetics and safety of fosfomycin and flomoxef administered as part of neonatal sepsis treatment (NeoSep1 Part 1)
Neonatal doses for the off-patent antibiotics fosfomycin and flomoxef, flomoxef,which offer coverage against many extended-spectrum beta-lactamase (ESBL)-producing organisms, are based on limited data. We performed a pharmacokinetic (PK) and safety study of fosfomycin and flomoxef to confirm proposed neonatal dosing before further investigation in a trial (NeoSep1, ISRCTN48721236).
Authors
Adrie Bekker, Navarat Panjasawatwong, Louise F. Hill, Wolfgang Stohr, A. Sarah Walker, Sally Ellis, Angela Dramowski, Andrew Whitelaw, Christina Obiero, James A. Berkley, Alexander Makazi, Sithembiso Velaphi, Reenu Thomas, Petronella Magagula, Ilhaam Abrahams, Firdose L. Nakwa, Mohammed M. Barday, Alison Van Kwawegen, Kamla Pillay, Silke Gastine, Joseph F. Standing, Peter Skoutari, Francesca Schiavone, Mike Sharland, Seamus O’Brien, Julia A. Bielicki, Tim R. Cressey, On behalf of the NeoSep Study Team